Nusinersen Versus Sham Control in Later-Onset Spinal Muscular Atrophy
NEJM 378:625-635, Mercuri, E.,et al, 2018
Single-Dose Gene-Replacement Therapy for Spinal Muscular Atrophy
NEJM 377:1713-1722,1786, Mendell, J.R.,et al, 2017
Powassan Virus-A New Reemerging Tick-Borne Disease
Front Public Health 5:342, Fatmi,S.S., et al, 2017
Non-Alzheimers Dementia 1 Frontotemporal Dementia
Lancet 386:1672-1682, Bang, Jee.,et al, 2015
Clinicopath Conf., Multifocal Motor Neuropathy With Conduction Block
NEJM 357: 2707-2715, Case 40-2007, 2007
Clinicopath Conf,Encephalomyelitis Due to West Nile Virus and CLL, Case 22-2005
NEJM 353:287-295, Hollande,H.,et al, 2005
Development of General Weakness in a Patient with Amyotrophic Lateral Sclerosis after Focal Botulinum Toxin Injection
Neurol 46:845-846, Mezaki,T.,et al, 1996
Riluzole
Lancet 348:795-799, Wokke,J., 1996
A Controlled Trial of Riluzole in Amyotrophic Lateral Sclerosis
NEJM 330:585-591, Bensimon,G.,et al, 1994
Growth Factors:Potential Therapeutic Applications in Neurology
JNNP 54:1445-1450, Drago,J.,et al, 1994
Differential Diagnosis of Guillain-Barre Synd, In Guillain-Barre Synd
Thieme Med Publ, Ch 3, p 42993., Parry,G.J., 1993
GM-1 Ganglioside for Spinal-Cord Injury
NEJM 326:493, Schonhofer,P.S., 1992
Lower Motor Neuron Disease in a Patient with Autoantibodies Against Gangliosides GM1 and GD1b:Improvement with Immunotherapy
Neurol 40:842-844, Shy,M.E.,et al, 1990
Motoneuron Disease:A Disorder Secondary to Solvent Exposure?
Lancet 1:73-76, 82-831989., Hawkes,C.H.,et al, 1989
Neurological Clues from Environmental Neurotoxins
BMJ 295:346-347, Martyn,C.N., 1987
Alzheimer's Disease, Parkinson's Disease, & Motoneurone Disease:Abiotropic Interaction Between Ageing & Environment
Lancet 2:1067-1068, Calne,D.B.,et al, 1986
Isolation of LAV/HTLV-III From a Patient with Amyotrophic Lateral Sclerosis
NEJM 313:324-325, Hoffman,P.M.,et al, 1985